Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Single-agent gemcitabine in elderly patients with unresectable biliary tract cancer.

Kuriyama H, Kawana K, Taniguchi R, Jono F, Sakai E, Okubo H, Suzuki H, Kobayashi S, Murata Y, Inamori M, Hata Y, Nakajima A.

Hepatogastroenterology. 2011 Jan-Feb;58(105):26-30.

PMID:
21510281
2.

Single-agent gemcitabine in elderly patients with unresectable biliary tract cancer.

Kuriyama H, Kawana K, Taniguchi R, Jono F, Sakai E, Ohubo H, Suzuki H, Kobayashi S, Murata Y, Inamori M, Hata Y, Nahajima A.

Hepatogastroenterology. 2011 Mar-Apr;58(106):270-4.

PMID:
21661380
3.

Effect of low-dose gemcitabine on unresectable pancreatic cancer in elderly patients.

Matsumoto K, Miyake Y, Kato H, Kawamoto H, Imagawa A, Toyokawa T, Nakatsu M, Ando M, Hirohata M, Yamamoto K.

Digestion. 2011;84(3):230-5. doi: 10.1159/000330384. Epub 2011 Aug 23.

PMID:
21860243
4.

Efficacy and safety of gemcitabine monotherapy for patients with advanced biliary tract cancer.

Yokoyama T, Yoshida H, Makino H, Maruyama H, Suzuki S, Matsutani T, Matsushita A, Hirakata A, Sasajima K, Uchida E.

J Nippon Med Sch. 2012;79(3):204-12.

5.

Single-agent gemcitabine in the treatment of advanced biliary tract cancers: a phase II study.

Park JS, Oh SY, Kim SH, Kwon HC, Kim JS, Jin-Kim H, Kim YH.

Jpn J Clin Oncol. 2005 Feb;35(2):68-73.

PMID:
15709089
6.

Efficacy and safety of metallic stents in patients with unresectable pancreatic cancer receiving gemcitabine.

Nakai Y, Isayama H, Kawabe T, Tsujino T, Yoshida H, Sasaki T, Tada M, Arizumi T, Yagioka H, Kogure H, Togawa O, Ito Y, Matsubara S, Hirano K, Sasahira N, Omata M.

Pancreas. 2008 Nov;37(4):405-10. doi: 10.1097/MPA.0b013e3181706d93.

PMID:
18953253
7.

Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer.

Lee S, Oh SY, Kim BG, Kwon HC, Kim SH, Rho MH, Kim YH, Rho MS, Jeong JS, Kim HJ.

Am J Clin Oncol. 2009 Aug;32(4):348-52. doi: 10.1097/COC.0b013e31818c08ff.

PMID:
19363436
8.

Treatment efficacy/safety and prognostic factors in patients with advanced biliary tract cancer receiving gemcitabine monotherapy: an analysis of 100 cases.

Suzuki E, Furuse J, Ikeda M, Okusaka T, Nakachi K, Mitsunaga S, Ueno H, Morizane C, Kondo S, Shimizu S, Kojima Y, Hagihara A.

Oncology. 2010;79(1-2):39-45. doi: 10.1159/000318020. Epub 2010 Nov 10.

PMID:
21063134
9.

Safety and effectiveness of gemcitabine in 260 patients with biliary tract cancer in a Japanese clinical practice based on post-marketing surveillance in Japan.

Okubo S, Nishiuma S, Kobayashi N, Taketsuna M, Taniai H.

Jpn J Clin Oncol. 2012 Nov;42(11):1043-53. doi: 10.1093/jjco/hys149. Epub 2012 Oct 5.

PMID:
23042772
10.

Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer.

Okusaka T, Ishii H, Funakoshi A, Yamao K, Ohkawa S, Saito S, Saito H, Tsuyuguchi T.

Cancer Chemother Pharmacol. 2006 May;57(5):647-53. Epub 2005 Sep 2.

PMID:
16142487
11.

Single-agent gemcitabine for biliary tract cancers. Study outcomes and systematic review of the literature.

Kiba T, Nishimura T, Matsumoto S, Hatano E, Mori A, Yasumi S, Doi R, Ikai I, Kitano T, Nishimura T, Yoshikawa K, Ishiguro H, Yanagihara K, Doi E, Teramukai S, Fukushima M.

Oncology. 2006;70(5):358-65. Epub 2006 Dec 15. Review.

PMID:
17179730
12.

Phase II trial of weekly 24-hour infusion of gemcitabine in patients with advanced gallbladder and biliary tract carcinoma.

von Delius S, Lersch C, Schulte-Frohlinde E, Mayr M, Schmid RM, Eckel F.

BMC Cancer. 2005 Jun 12;5:61.

13.

Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer.

Hong YS, Lee J, Lee SC, Hwang IG, Choi SH, Heo JS, Park JO, Park YS, Lim HY, Kang WK.

Cancer Chemother Pharmacol. 2007 Aug;60(3):321-8. Epub 2006 Dec 2.

PMID:
17143602
14.

Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.

Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J; ABC-02 Trial Investigators.

N Engl J Med. 2010 Apr 8;362(14):1273-81. doi: 10.1056/NEJMoa0908721.

15.

A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer.

Suzuki E, Ikeda M, Okusaka T, Nakamori S, Ohkawa S, Nagakawa T, Boku N, Yanagimoto H, Sato T, Furuse J.

Cancer Chemother Pharmacol. 2013 May;71(5):1141-6. doi: 10.1007/s00280-013-2106-0. Epub 2013 Mar 24.

16.

A Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer.

Kim ST, Park JO, Lee J, Lee KT, Lee JK, Choi SH, Heo JS, Park YS, Kang WK, Park K.

Cancer. 2006 Mar 15;106(6):1339-46.

17.

Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer.

Park BK, Kim YJ, Park JY, Bang S, Park SW, Chung JB, Kim KS, Choi JS, Lee WJ, Song SY.

J Gastroenterol Hepatol. 2006 Jun;21(6):999-1003.

PMID:
16724985
18.

A multi-center retrospective analysis of survival benefits of chemotherapy for unresectable biliary tract cancer.

Yonemoto N, Furuse J, Okusaka T, Yamao K, Funakoshi A, Ohkawa S, Boku N, Tanaka K, Nagase M, Saisho H, Sato T.

Jpn J Clin Oncol. 2007 Nov;37(11):843-51. Epub 2007 Oct 17.

PMID:
17942578
19.

Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma.

Cho JY, Paik YH, Chang YS, Lee SJ, Lee DK, Song SY, Chung JB, Park MS, Yu JS, Yoon DS.

Cancer. 2005 Dec 15;104(12):2753-8.

20.

A retrospective study of S-1 monotherapy as second-line treatment for patients with advanced biliary tract cancer.

Kobayashi S, Ueno M, Ohkawa S, Andou T, Kameda R, Yamamoto N, Morinaga S.

Jpn J Clin Oncol. 2012 Sep;42(9):800-6. doi: 10.1093/jjco/hys102. Epub 2012 Jul 23.

PMID:
22826349

Supplemental Content

Support Center